Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

NCT02141828 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT02141828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02141828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
June 30, 2016
Enrollment
18 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemias, acute lymphocytic leukemia, acute myeloid leukemia, leukemia